Abstract:Aberrant expression of the RON receptor tyrosine kinase, a member of the MET proto-oncogene family, in breast cancer and non-small cell lung cancer (NSCLC) has therapeutic implication. Here we evaluated the efficacy of a novel anti-RON antibody-drug maytansinoid conjugate Zt/g4-DM1 for treatment of breast and NSCLC xenograft tumors in mouse models and explored a treatment strategy by combination of Zt/g4-DM1 with chemotherapeutics to achieve the maximal therapeutic activity.

Correction to "α 3 β 1 Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment"

Correction to "Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting"

Corrigendum: Docetaxel-loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Correction to "Targeted Chemo-Photodynamic Combination Platform Based on the DOX Prodrug Nanoparticles for Enhanced Cancer Therapy"

Correction to "Janus ACSP Nanoparticle for Synergistic Chemodynamic Therapy and Radiosensitization"

Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Correction to "Self-Stimulated Photodynamic Nanoreactor in Combination with CXCR4 Antagonists for Antileukemia Therapy''

Correction to "Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer"

Correction: Ce6-Conjugated and Polydopamine-Coated Gold Nanostars with Enhanced Photoacoustic Imaging and Photothermal/photodynamic Therapy to Inhibit Lung Metastasis of Breast Cancer.

Correction to "Self-Assembled 2D Glycoclusters for the Targeted Delivery of Theranostic Agents to Triple-Negative Breast Cancer Cells"

Erratum To: Biological Evaluation of Antibody-Maytansinoid Conjugates As a Strategy of RON Targeted Drug Delivery for Treatment of Non-Small Cell Lung Cancer

Corrigendum to "Emulsifying Lipiodol with pH-Sensitive DOX@HmA nanoparticles for hepatocellular carcinoma TACE treatment eliminate metastasis" Mater. Today Bio, 23, 2023, 100873, ISSN 2590-0064

Correction to "Co-Delivery of Astaxanthin and si TGF-β 1 via Ionizable Liposome Nanoparticles for Improved Idiopathic Pulmonary Fibrosis Therapy"

Correction: Tumor-targeting, enzyme-activated nanoparticles for simultaneous cancer diagnosis and photodynamic therapy

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Correction: Photodynamic antitumor activity of aggregation-induced emission luminogens as chemosensitizers for paclitaxel by concurrent induction of apoptosis and autophagic cell death

Correction: Recent advances in cell membrane coated metal–organic frameworks (MOFs) for tumor therapy

Correction to "Unleashing the Potential of Camptothecin: Exploring Innovative Strategies for Structural Modification and Therapeutic Advancements"

Erratum: Addition and Correction to "High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles"

Correction: an Oxygen Self-Sufficient NIR-responsive Nanosystem for Enhanced PDT and Chemotherapy Against Hypoxic Tumors

Correction to "Light-Activable On-Demand Release of Nano-Antibiotic Platforms for Precise Synergy of Thermochemotherapy on Periodontitis"